News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Opinion|Videos|May 9, 2024

Potential Novel Schizophrenia Treatments

Author(s)John M. Kane, MD, Erin Crown, MHS, PA-C, Psych-CAQ

A comprehensive discussion on new treatment options for patients with schizophrenia, highlighting the potential for earlier intervention to optimize treatment outcomes.

Episodes in this series

EP. 1 Burden, Stigma, and Prevalence of Schizophrenia

EP. 1 Burden, Stigma, and Prevalence of Schizophrenia

Video 2 - "Exploration into the Management of the Three Symptom Domains of Schizophrenia"

EP. 2 Exploration into the Management of the Three Symptom Domains of Schizophrenia

Video 3 - "Insights on the Pathophysiology of Schizophrenia"

EP. 3 Insights on the Pathophysiology of Schizophrenia

Video 4 - "Physician Awareness of Cognitive Dysfunction in Schizophrenia"

EP. 4 Physician Awareness of Cognitive Dysfunction in Schizophrenia

Erin Crown, PA-C, CAQ-Psychiatry, and John M. Kane, MD, experts on schizophrenia

EP. 5 Potential Novel Schizophrenia Treatments

Video 6 - "Future Perspectives on Schizophrenia Care"

EP. 6 Future Perspectives on Schizophrenia Care

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Gus Alva, MD, on Agitation, Psychosis, and Cognition in Alzheimer Disease

Gus Alva, MD, on Agitation, Psychosis, and Cognition in Alzheimer Disease

ByGustavo Alva, MD, DFAPA

July 31st 2026

schizophrenia

Real-World and Long-Term Trial Data Show Xanomeline/Trospium Cuts Hospitalizations, Antipsychotic Burden in Schizophrenia

ByPsychiatric Times Editors

July 30th 2026

schizophrenia

PET Imaging Confirms Lower Muscarinic M1 Receptor Availability in Schizophrenia

ByPatrick Campbell

July 29th 2026

categories

Categories vs Dimensions: Wave or Particle?

ByS. Nassir Ghaemi, MD, MPH,Mark L. Ruffalo, MSW, DPsa

July 29th 2026

biomarker

Novel CSF Biomarker and Peptide Candidate Target Cognitive Symptoms of Schizophrenia

ByPatrick Campbell

July 28th 2026

Latest CME

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

PET Imaging Confirms Lower Muscarinic M1 Receptor Availability in Schizophrenia

What's New in Psychiatric Treatment? Highlights From the 2026 Southern California Psychiatry Conference

A Preventive Window In Post-TBI Care and Subsequent Alzheimer Pathology

From Fibromyalgia to Depression: TNX-102 Sublingual Cyclobenzaprine Trials for MDD

A New Mechanism for ADHD: Raman Baweja, MD, on Centanafadine's FDA Approval